Crispr Therapeutics Ag Stock Price on December 12, 2024
| CRSP Stock | USD 40.94 0.46 1.14% |
Below is the normalized historical share price chart for Crispr Therapeutics AG extending back to October 19, 2016. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Crispr Therapeutics stands at 40.94, as last reported on the 26th of December, with the highest price reaching 41.02 and the lowest price hitting 39.80 during the day.
If you're considering investing in Crispr Stock, it is important to understand the factors that can impact its price. Crispr Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0519, which signifies that the company had a -0.0519% return per unit of risk over the last 3 months. Crispr Therapeutics AG exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Crispr Therapeutics' Risk Adjusted Performance of (0.03), mean deviation of 2.37, and Standard Deviation of 3.3 to double-check the risk estimate we provide.
As of 12/26/2024, Other Stockholder Equity is likely to grow to about 3 B, while Total Stockholder Equity is likely to drop slightly above 1 B. . At this time, Crispr Therapeutics' Price Book Value Ratio is relatively stable compared to the past year. As of 12/26/2024, Price Earnings To Growth Ratio is likely to grow to 0.44, though Price To Operating Cash Flows Ratio is likely to grow to (18.09). Crispr Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 19th of October 2016 | 200 Day MA 53.641 | 50 Day MA 48.2422 | Beta 1.662 |
Crispr |
Sharpe Ratio = -0.0519
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CRSP |
Estimated Market Risk
| 3.36 actual daily | 29 71% of assets are more volatile |
Expected Return
| -0.17 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Crispr Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Crispr Therapeutics by adding Crispr Therapeutics to a well-diversified portfolio.
Price Book 1.8015 | Enterprise Value Ebitda 14.1584 | Price Sales 17.2282 | Shares Float 83.9 M | Wall Street Target Price 81.75 |
Related Headline
Beam Therapeutics Headline on 12th of December 2024
HC Wainwright Reaffirms Buy Rating for Beam Therapeutics by thelincolnianonline.com
HC Wainwright restated their buy rating on shares of Beam Therapeutics in a report issued on Monday,Benzinga reports. The brokerage currently has a 80.00 target price on the stock. A number of other equities research analysts have also issued reports on the company. Stifel Nicolaus upped their price target on Beam
Crispr Therapeutics Valuation on December 12, 2024
It is possible to determine the worth of Crispr Therapeutics on a given historical date. On December 12, 2024 Crispr was worth 47.41 at the beginning of the trading date compared to the closed value of 45.4. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Crispr Therapeutics stock. Still, in general, we apply an absolute valuation method to find Crispr Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Crispr Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Crispr Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 49.00 | 49.38 | 47.35 | 47.78 | 1,507,167 | |
12/12/2024 | 47.41 | 47.68 | 45.39 | 45.40 | 1,974,155 |
| 45.01 | 45.34 | 42.86 | 43.78 | 3,191,323 |
| Backtest Crispr Therapeutics | | | Crispr Therapeutics History | | | Crispr Therapeutics Valuation | Previous | Next |
Crispr Therapeutics Trading Date Momentum on December 12, 2024
| On December 13 2024 Crispr Therapeutics AG was traded for 43.78 at the closing time. The top price for the day was 45.34 and the lowest listed price was 42.86 . The trading volume for the day was 3.2 M. The trading history from December 13, 2024 was a factor to the next trading day price decrease. The overall trading delta against the next closing price was 3.57% . The overall trading delta against the current closing price is 10.09% . |
Crispr Therapeutics Fundamentals Correlations and Trends
By evaluating Crispr Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Crispr Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Crispr financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Crispr Therapeutics Stock history
Crispr Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Crispr is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Crispr Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Crispr Therapeutics stock prices may prove useful in developing a viable investing in Crispr Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 79.2 M | 57.1 M | |
| Net Loss | -585.2 M | -555.9 M |
Crispr Therapeutics Quarterly Net Working Capital |
|
Crispr Therapeutics Stock Technical Analysis
Crispr Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Crispr Therapeutics Period Price Range
Low | December 26, 2024
| High |
0.00 | 0.00 |
Crispr Therapeutics AG cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Crispr Therapeutics December 26, 2024 Market Strength
Market strength indicators help investors to evaluate how Crispr Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Crispr Therapeutics shares will generate the highest return on investment. By undertsting and applying Crispr Therapeutics stock market strength indicators, traders can identify Crispr Therapeutics AG entry and exit signals to maximize returns
Crispr Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Crispr Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Crispr Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Crispr to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.22) | |||
| Total Risk Alpha | (0.30) | |||
| Treynor Ratio | (0.09) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.